

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GenFleet Therapeutics (Shanghai) Inc.

勁方醫藥科技(上海)股份有限公司

*(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2595)*

PROPOSED ABOLISHMENT OF THE SUPERVISORY COMMITTEE AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION

The board (the “**Board**”) of directors (“**Director(s)**”) of GenFleet Therapeutics (Shanghai) Inc. (the “**Company**”) hereby announces that the Company intends to put forward proposals to the shareholders of the Company (the “**Shareholders**”) to abolish the supervisory committee of the Company (the “**Supervisory Committee**”) and amend the existing articles of association of the Company (the “**Articles of Association**”).

PROPOSED ABOLISHMENT OF THE SUPERVISORY COMMITTEE AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION

On December 29, 2023, the amendments to the Company Law of the PRC (《中華人民共和國公司法》) (the “**PRC Company Law**”) was adopted, which came into effect on July 1, 2024. The amendments introduced by the new PRC Company Law include but not limited to reforming the corporate capital system and organizational structure, enhancement in protection for minority shareholders’ rights and interests, strengthening responsibilities for controlling shareholders, directors and senior management as well as permitting the replacement of supervisory committee with audit committee. In order to ensure the listed companies can effectively comply with and implement the new requirements of the PRC Company Law, the China Securities Regulatory Commission issued a number of important documents on 28 March 2025, including the revised Guidelines on the Articles of Association of Listed Companies (《上市公司章程指引》).

In light of the above, the Board proposed to make certain amendments to the existing Articles of Association, mainly including but not limited to (1) the abolition of the Supervisory Committee and the exercise of its functions and powers by the audit committee of the Board as stipulated by the PRC Company Law; (2) enhancing protection for the rights of Shareholders; (3) consequential amendments to the provisions of the Articles of Association in accordance with changes in applicable laws and regulations; and (4) other internal affairs and miscellaneous changes (the “**Proposed Amendments**”).

Each of the supervisors of the Company (the “**Supervisor(s)**”) will resign as a Supervisor conditional upon the approval of the proposed abolishment of the Supervisory Committee at the EGM and with effect from the date of EGM (as defined below). Each of the Supervisors has confirmed that he/she has no disagreement with the Board and Supervisory Committee, and that there is no other matter in relation to his/her resignation that needs to be brought to the attention of the Shareholders.

According to the Articles of Association and the relevant laws and regulations, the Proposed Amendments will take effect subject to the approval of the Shareholders at the extraordinary general meeting of the Company (the “**EGM**”) by way of a special resolution. A special resolution to consider and approve the Proposed Amendments will be proposed at the EGM in due course.

A circular of the Company in relation to the EGM containing, among others, further details of the Proposed Amendments, will be despatched to the Shareholders in due course.

EGM

Reference is made to the announcement (the “**Announcement**”) of the Company dated November 24, 2025, in relation to the proposed adoption of the H Share Option Scheme and the H Share Incentive Scheme. Unless otherwise stated, the terms used under this section shall have the same meaning as defined in the Announcement.

The EGM will be held at 10:00 a.m. on Monday, February 9 2026 at Room 212, Building A, 1206 Zhangjiang Road, (Shanghai) Pilot Free Trade Zone, PRC, for the Shareholders to consider and approve (if thought fit) by way of special resolutions, (i) the proposed adoption of the H Share Option Scheme; (ii) the proposed adoption of the H Share Incentive Scheme; (iii) the proposed authorization to the Board and/or authorized person(s) to handle matters related to the H Share Option Scheme and the H Share Incentive Scheme; (iv) the proposed grant of general mandate to repurchase shares; (v) proposed abolishment of the Supervisory Committee and amendments to the Articles of Association; and (vi) other matters contained in the notice of EGM. A circular, containing details of the abovementioned proposals and relevant information, together with the notice of the EGM and the form of proxy for use at the EGM, will be published on the website of the Stock Exchange (www.hkexnews.hk) and the website of the Company (www.genfleet.com).

The record date for the purpose of determining the eligibility of the Shareholders to attend and vote at the EGM is Monday, February 9, 2026. For the purpose of ascertaining the entitlement of the Shareholders who are eligible to attend and vote at the EGM, the register of Shareholders will be closed from Wednesday, February 4, 2026 to Monday, February 9, 2026 (both days inclusive). Holders of H Shares who intend to attend the EGM are required to lodge all completed transfer documents accompanied by the relevant share certificates with the Company's H Share registrar, Computershare Hong Kong Investor Services Limited at Shop 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong on or before 4:30 p.m. on Tuesday, February 3, 2026 for registration. Holders of unlisted shares of the Company who intend to attend the EGM are required to lodge all completed transfer documents accompanied by the relevant share certificates at the office of the Company, at Room 211, Building A, 1206 Zhangjiang Road, (Shanghai) Pilot Free Trade Zone, PRC on or before 4:30 p.m. on Tuesday, February 3, 2026 for registration.

By order of the Board
GenFleet Therapeutics (Shanghai) Inc.
Dr. Qiang LU
Chairman and Executive Director

Hong Kong, January 20, 2026

As at the date of this announcement, the Board of the Company comprises: (i) Dr. Qiang LU, Dr. Jiong LAN and Ms. ZHANG Wei as executive Directors; (ii) Mr. ZHU Jingyang and Ms. TAO Sha as non-executive Directors; and (iii) Ms. Christine Shaohua LU-WONG, Dr. ZHOU Demin and Mr. LI Bo as independent non-executive Directors.